Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction-Reference-Cited by-同舟云学术

Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction

Published:2018-11-28 Issue:4 Volume:46 Page:889-900
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Müller Julian,Ferraro Daniela A.,Muehlematter Urs J.,Garcia Schüler Helena I.,Kedzia Sarah,Eberli Daniel,Guckenberger Matthias,Kroeze Stephanie G. C.,Sulser Tullio,Schmid Daniel M.,Omlin Aurelius,Müller Alexander,Zilli Thomas,John Hubert,Kranzbuehler Helmut,Kaufmann Philipp A.,von Schulthess Gustav K.,Burger Irene A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-018-4203-0.pdf

Reference52 articles.

1. Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68. https://doi.org/10.1007/s00259-017-3711-7 .

2. Eissa A, El Sherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of literature. Minerva Urol Nefrol. 2018;70:462–78. https://doi.org/10.23736/S0393-2249.18.03081-3 .

3. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. https://doi.org/10.2967/jnumed.115.160382 .

4. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:92–101. https://doi.org/10.1007/s00259-016-3490-6 .

5. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. (68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–7. https://doi.org/10.2967/jnumed.117.201749 .

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Added Value of [18F]PSMA‐1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management;Journal of Magnetic Resonance Imaging;2024-04-28

2. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature;European Urology Oncology;2024-02

3. 68Ga-PSMA;Radiopharmaceuticals;2024

4. PSMA Targeted Ligands in Imaging and Theranostics for Prostate Cancer;The Bulletin of Urooncology;2023-12-04

5. PSMA guided approach for bIoCHEmical relapse after prostatectomy‐ (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga‐PSMA PET/CT within a prospective study;The Prostate;2023-06-08